Last reviewed · How we verify
Endocalyx
Endocalyx is a Small molecule drug developed by VA Office of Research and Development. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Endocalyx |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes (PHASE2, PHASE3)
- Endocalyx in Treatment Resistent Hypertension (PHASE2)
- Restoring Glycocalyx Thickness in Older Adults to Improve Vascular Function (NA)
- Endocalyx for Heart Failure (PHASE2)
- The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis (NA)
- The Effect of Dietary Intervation on Endothelial Glycocalyx in COVID-19 Patients. (NA)
- Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endocalyx CI brief — competitive landscape report
- Endocalyx updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI
Frequently asked questions about Endocalyx
What is Endocalyx?
Who makes Endocalyx?
What development phase is Endocalyx in?
Related
- Manufacturer: VA Office of Research and Development — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing